ARQT logo

ARQT
Arcutis Biotherapeutics Inc

2,499
Mkt Cap
$3.1B
Volume
2.3M
52W High
$27.08
52W Low
$8.29
PE Ratio
-71.40
ARQT Fundamentals
Price
$25.31
Prev Close
$24.92
Open
$24.69
50D MA
$18.92
Beta
1.34
Avg. Volume
1.85M
EPS (Annual)
-$1.16
P/B
19.26
Rev/Employee
$574,684.21
Loading...
Loading...
News
all
press releases
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·2d ago
News Placeholder
More News
News Placeholder
What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock
Arcutis Biotherapeutics (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·2d ago
News Placeholder
Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year?
Here is how Grifols (GRFS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Zacks·2d ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +160.00% and +14.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·11d ago
News Placeholder
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·27d ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·1mo ago
News Placeholder
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·1mo ago
News Placeholder
Are Medical Stocks Lagging AxoGen (AXGN) This Year?
Here is how AxoGen (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Zacks·2mo ago

Latest ARQT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.